Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics
Bidridistrogene xeboparvovec is an AAV-based gene therapy delivering a copy of the human SGCB gene, given as a single intravenous infusion. It is being studied in limb-girdle muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06246513 | Phase 3 | Limb-girdle Muscular Dystrophy | Active not recruiting | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Limb-girdle Muscular Dystrophy
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →